Metabolic & Cardiometabolic
SGLT1 inhibition increases GLP-1 secretion
📅 Last reviewed: 2026-08-11 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
The premise behind shunting glucose distally to trigger L-cells — and the human evidence is genuinely split, which matters because a whole formulation strategy rests on it. The Lexicon LX4211 trials report increased total GLP-1 and PYY. But a Copenhagen crossover in RYGB patients found SGLT1/2 inhibition did not raise 4-hour GLP-1 iAUC (p=0.
The evidence (4)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA, Ruff D, Powell D, Sands A 2013 · Clin Ther. 2013 Aug;35(8):1162-1173.e8 (Epub 2013 Jul 31) | RCT | supports | low | Randomized, double-blind, placebo-controlled multiple-dose dose-timing study, n=12 healthy subjects aged 30-51 (NCT01334242). 'Treatment with LX4211 resulted in significant elevation of total and active GLP-1, and PYY while significantly decreasing PPG levels relative to placebo, likely by reducing SGLT1-mediated intestinal glucose absorption.' Quality low: n=12, all ten authors are Lexicon Pharmaceuticals staff reporting the sponsor's own molecule, LX4211 is a DUAL SGLT1/SGLT2 inhibitor so the SGLT1 attribution is the authors' inference from schedule comparisons ('distinct SGLT1 effects ... separate from SGLT2-mediated effects'), and no magnitude, CI or p-value is recoverable - the paper is not open access, so abstract is the ceiling. |
| Martinussen C, et al. 2020 · American journal of physiology. Endocrinology and metabolism | RCT | contradicts | moderate | Randomized controlled crossover, n=10 RYGB patients, 50 g oral glucose +/- acute 600 mg canagliflozin (dual SGLT1/SGLT2). Primary outcome NULL: 'did not reduce iAUC GLP-1 (6,067 vs. 7,273 min.pmol-1.L-1, P = 0.23)' - note the abstract does not label the arms, and the tracer and glucagon pairs imply control-first ordering, so the 4-h total may have been numerically HIGHER on canagliflozin; the total is uninformative either way. The significant findings run against the claim: 'peak GLP-1 concentrations were lowered (-28%, P = 0.03)' and GIP 'iAUC -28%, P = 0.01; peak concentrations -57%, P < 0.01'. Authors conclude 'SGLT1-mediated glucose absorption contributes to incretin hormone secretion after RYGB' - i.e. blocking SGLT1 mutes, not boosts, the early incretin response. Quality moderate not high: abstract-only provenance (CONVENTIONS 7 caps it), n=10, single acute dose, surgically altered anatomy, blinding not stated, and a dual SGLT1/SGLT2 agent so SGLT1-specific attribution is inferential. |
| Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D 2013 · Clin Ther. 2013 Mar;35(3):273-285.e7 (Epub 2013 Feb 21) | RCT | supports | low | Lexicon LX4211 programme, NCT01441232; '3-treatment, 3-crossover, randomized, open-label study ... at a single center', single dose, n=18 T2DM washed out from metformin, no placebo arm. Monotherapy result — the one that speaks to the claim: 'LX4211 was associated with a significant increase in total GLP-1 and PYY and a reduced total GIP, likely due to a reduction in SGLT1-mediated intestinal glucose absorption, whereas sitagliptin was associated with suppression of all 3 peptides relative to baseline.' The active-GLP-1 gain is reported for the combination and ONLY against sitagliptin: 'The LX4211 + sitagliptin combination was associated with significantly increased active GLP-1, total GLP-1, and total PYY ... compared with sitagliptin monotherapy.' The 'synergy versus either agent' belongs to the MOUSE experiment, not the patients: 'With repeat daily dosing, the combination was associated with apparently synergistic increases in active GLP-1 relative to monotherapy with either agent.' Attribution to SGLT1 is the authors' own inference ('likely due to'), the agent is a dual SGLT1/SGLT2 inhibitor, no effect size or p-value is recoverable at abstract grade (not open access, not in PMC), and all 11 authors are Lexicon Pharmaceuticals staff. Same lexicon-sglt1 group as s23911260 and s31837264. |
| Io F, et al. 2019 · European journal of pharmacology | animal | supports | moderate | SGL5213 enhanced plasma total GLP-1 and GLP-2 in rats and delivered unabsorbed glucose to caecum/colon at 3-9h, supporting the distal-delivery mechanism. Rat; timing of the GLP-1 rise is delayed relative to a meal. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.